The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies Meeting Abstract
| Authors: | Zain, D. R.; Iyer, S. P.; Sica, R. A.; Ho, P. J.; Hu, B.; Prica, A.; Weng, W. K.; Kim, Y. H.; Khodadoust, M. S.; Palomba, M. L.; Foss, F. M.; Tipton, K.; Cullingford, E. L.; Horwitz, S. M.; Sharma, A.; Horwitz, S. M. |
| Abstract Title: | The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies |
| Meeting Title: | EORTC CLTG Meeting on Cutaneous Lymphomas: From Molecules to PROs |
| Journal Title: | European Journal of Cancer |
| Volume: | 173 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Sep 22-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-09-01 |
| Start Page: | S21 |
| Language: | English |
| ACCESSION: | WOS:000872008600045 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(22)00591-3 |
| Notes: | Meeting Abstract: Ther-O-02 -- Oral Presentation: Therapeutics -- Source: Wos |
